{
    "Trade/Device Name(s)": [
        "CAPI 3 Hb A1c"
    ],
    "Submitter Information": "Sebia, Inc.",
    "510(k) Number": "K171537",
    "Predicate Device Reference 510(k) Number(s)": [
        "K131580"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ"
    ],
    "Summary Letter Date": "July 24, 2017",
    "Summary Letter Received Date": "July 27, 2017",
    "Submission Date": "August 14, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.1373"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c (HbA1c)"
    ],
    "Specimen Type(s)": [
        "Venous whole blood",
        "Whole human blood"
    ],
    "Specimen Container(s)": [
        "Test tube",
        "Tube",
        "Reagent cup"
    ],
    "Instrument(s)/Platform(s)": [
        "CAPILLARYS 3 TERA instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Capillary electrophoresis"
    ],
    "Methodologies": [
        "Separation and quantification of HbA1c by capillary electrophoresis"
    ],
    "Submission Type(s)": [
        "Kit",
        "Reagent",
        "Analyzer"
    ],
    "Document Summary": "FDA 510(k) summary for Sebia CAPI 3 Hb A1c kit utilizing capillary electrophoresis for HbA1c quantification on the CAPILLARYS 3 TERA instrument",
    "Indications for Use Summary": "Intended for separation and quantification of the HbA1c glycated fraction of hemoglobin in venous whole human blood by capillary electrophoresis with the CAPILLARYS 3 TERA instrument, as an aid in diabetes diagnosis, identifying at-risk patients, and monitoring long-term glucose control.",
    "fda_folder": "Clinical Chemistry"
}